Literature DB >> 11128727

Radioiodine and percutaneous ethanol injection in the treatment of large toxic thyroid nodule: a long-term study.

M Zingrillo1, M Torlontano, M R Ghiggi, V Frusciante, A Varraso, A Liuzzi, V Trischitta.   

Abstract

Surgery is generally recommended for large thyroid toxic nodules (TTNs). When surgery is not applicable, both radioactive iodine (RAI) and percutaneous ethanol injection (PEI) are alternative treatments. In this retrospective study, the long-term efficacy of nonsurgical treatments was evaluated in 43 patients with TTN, selected on the basis of presence of hyperthyroidism and a fairly large nodule (3- and 4-cm in diameter) completely inhibiting controlateral lobe captation during scintigraphy. Twenty-one patients were treated by RAI (administered dose 670+/-160 MBq; range 555-925) and twenty-two were treated by PEI (6+/-1 sessions; range 5-9). FT4, FT3, thyrotropin (TSH), and nodule volume were assessed before and at fixed intervals after treatment. Median follow-up was 36 months (range, 12-84). Compared to baseline values, with both therapies, serum FT4, FT3, and nodule volume were decreased (p < 0.01) and serum TSH was increased (p < 0.01), after 3 months and during the entire follow-up. Nodule volume reduction percentage was 66.8+/-22.0 and 78.4+/-18.0, in the RAI- and PEI-treated groups, respectively. At the end of follow-up, 34 patients were euthyroid (16 RAI- and 18 PEI-treated). Four RAI-treated patients (19%) showed slightly high TSH levels (4.2-5.3 mU/L), whereas three PEI-treated patients (13.6%) still had suppressed TSH levels, although being clinically asymptomatic. One RAI-treated patient (4.8%) showed overt hypothyroidism during the follow-up period and was then treated with L-thyroxin. One patient (4.6%), who was initially cured by PEI, became newly hyperthyroid during the follow-up period. Both treatments were well-tolerated. In conclusion, both of these nonsurgical treatments are effective and may be chosen also for relatively large TTNs. Specifically, RAI seems to be more effective for treating hyperthyroidism but has minimal sequelae of subclinical or clinical hypothyroidism, while, after PEI treatment the possibility of stable subclinical hyperthyroidism or hyperthyroidism relapse should be taken into account.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128727     DOI: 10.1089/thy.2000.10.985

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  4 in total

Review 1.  Efficacy of radiofrequency ablation in autonomous functioning thyroid nodules. A systematic review and meta-analysis.

Authors:  Roberto Cesareo; Andrea Palermo; Domenico Benvenuto; Eleonora Cella; Valerio Pasqualini; Stella Bernardi; Fulvio Stacul; Silvia Angeletti; Giovanni Mauri; Massimo Ciccozzi; Pierpaolo Trimboli
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  Treatment of hyperfunctioning thyroid nodules by percutaneous ethanol injection.

Authors:  Bagher Larijani; Mohammad Pajouhi; Hossein Ghanaati; Mohammad-Hassan Bastanhagh; Fereshteh Abbasvandi; Kazem Firooznia; Mahmood Shirzad; Mohammad-Reza Amini; Maryam Sarai; Nasreen Abbasvandi; Reza Baradar-Jalili
Journal:  BMC Endocr Disord       Date:  2002-12-06       Impact factor: 2.763

3.  Long-term outcome following laser therapy of benign cystic-solid thyroid nodules.

Authors:  Helle Døssing; Finn Noe Bennedbæk; Laszlo Hegedüs
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

4.  Ultrasound-Guided Percutaneous Ethanol Injection Protocol to Treat Solid and Mixed Thyroid Nodules.

Authors:  João Soares Felício; Antônio Maria Silva Conceição; Flávia Marques Santos; Michelle Masuyo Minami Sato; Fabíola de Arruda Bastos; Ana Carolina Contente Braga de Souza; Camila Cavalcante Koury; João Felício Abrahão Neto; Franciane Trindade Cunha de Melo; Carolina Tavares Carvalho; Thaís Pontes Arbage; Antonio Bentes de Figueiredo Junior; Hana Andrade de Rider Brito; Marcelo Oliveira Mourão Júnior; Fabricio de Souza Resende; Amanda Soares Peixoto; Karem Miléo Felício
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-06       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.